Unique Device Identification

Last updated

The Unique Device Identification (UDI) System is intended to assign a unique identifier to medical devices within the United States, Europe, China, South Korea, Saudi Arabia and Taiwan. [1] It was signed into law in the US on September 27, 2007, as part of the Food and Drug Administration Amendments Act (Section 226) of 2007.

Contents

United States

These harmonized pieces of legislation include language related to the establishment of a Unique Device Identification System. When implemented, the new system will always be in reverse mode :[ citation needed ]

A national UDI system will create a common vocabulary for reporting and enhance electronic tracking abilities. Currently, analysis of adverse event reports is limited by the fact that the specific devices involved in an incident are often not known with the required degree of specificity. Without a common vocabulary for medical devices, meaningful analysis based on data from existing voluntary systems is problematic. Reliable and consistent identification of medical devices would enable safety surveillance so that the FDA and manufacturers could better identify potential problems or device defects, and improve patient care.

The UDI is expected to improve patient safety (in part by helping to identify counterfeit products and by improving the ability of staff to distinguish between devices that are similar in appearance but serve different functions), [2] facilitate and improve the recall process, and create efficiencies within the medical system. [3]

In the most basic format, the UDI would be a coded number registered with standards organizations, and would incorporate a variety of information, including (but not limited to) the manufacturer of the device, expiry dates, the make and model of the device, and any special attributes that the device may possess. [4] In a medical sense, "device" refers to any product that is not pharmaceutical in nature, and while the FDA have been given approval to exempt some devices, Jay Crowely (who was responsible for implementing the UDI requirements in the Act), has expressed an intent to apply the UDI to "everything until somebody gives us good reason not to", (excluding devices which won't need identification). [5]

Following the passing of the Act, there were calls for the FDA to publish a timeline for the implementation of the UDI; [6] this was subsequently done. [7]

GUDID Submission
The Final Rule on Unique Device Identifiers also mandates medical device manufacturers to make a submission to the FDA's Global Unique Device Identification Database. The submission to the GUDID will include the Primary Device Identifier portion of the UDI as well as associated data attributes about each model or version number of the device.

Compliance with the submission component of UDI compliance is phased according to the Class of device. Class III device labelers must submit to the GUDID for all existing products by September 24, 2014. Labelers of Implantable, Life Supporting or Life Sustaining devices must submit to the GUDID by September 24, 2015. Class II labelers must comply with submission guidelines by September 24, 2016, and Class I labelers by September 24, 2018.

Submission to the GUDID may be made in one of two methods. The first method utilizes the FDA's GUDID Web Interface, which is meant for low volumes of GUDID submissions. The second method utilizes an HL7 SPL submission and is transmitted to the FDA through an Electronic Submission Gateway account.

Once the initial submission is made, labelers of medical devices must update the GUDID submission each time there is a change to the device attributes. While many device attributes may be updated once the device record is published within the GUDID, several attributes cannot be changed and will necessitate the labeler deactivate the existing submission and resubmit using a new Device Identifier.

European Union

The EU acted to adopt UDI and on April 5, 2017, under the Medical Devices Regulation (MDR) and In-vitro Diagnostic Regulation (IVDR), but adoption has been postponed to 2021; see Medical Device Regulation. The timelines for UDI marking of medical devices, direct marking of medical devices, and marking of IVD allow for a staggered introduction. [8]

The EU UDI scheme includes the so-called Basic UDI-DI, a regulatory identifier of a device and key to the EUDAMED database, that does not appear on the device packaging but has to be listed on the Declaration of Conformity. Devices and packaging are to be marked with a device identifier ("UDI-DI"), identifying manufacturer and product, and a production identifier ("UDI-PI)", consisting of, e.g., the LOT and/or expiration date. Custom-made and investigational devices are exempt from this requirement. The direct marking of reusable devices is also included in the regulation.

Legacy devices that do not have a previously assigned Basic UDI-DI, they are assigned an EUDAMED-DI for the purpose of registration in EUDAMED. [9] Instead of the UDI-DI, an EUDAMED ID can be assigned for registration. [10]

As of July 2022, the EU has recognized four UDI-DI issuing agencies: GS1 AISBL; Health Industry Business Communications Council (HIBCC); ICCBBA, and Informationsstelle für Arzneispezialitäten (IFA GmbH). [11]

See also

Related Research Articles

A quality management system (QMS) is a collection of business processes focused on consistently meeting customer requirements and enhancing their satisfaction. It is aligned with an organization's purpose and strategic direction. It is expressed as the organizational goals and aspirations, policies, processes, documented information, and resources needed to implement and maintain it. Early quality management systems emphasized predictable outcomes of an industrial product production line, using simple statistics and random sampling. By the 20th century, labor inputs were typically the most costly inputs in most industrialized societies, so focus shifted to team cooperation and dynamics, especially the early signaling of problems via a continual improvement cycle. In the 21st century, QMS has tended to converge with sustainability and transparency initiatives, as both investor and customer satisfaction and perceived quality are increasingly tied to these factors. Of QMS regimes, the ISO 9000 family of standards is probably the most widely implemented worldwide – the ISO 19011 audit regime applies to both and deals with quality and sustainability and their integration.

A medical classification is used to transform descriptions of medical diagnoses or procedures into standardized statistical code in a process known as clinical coding. Diagnosis classifications list diagnosis codes, which are used to track diseases and other health conditions, inclusive of chronic diseases such as diabetes mellitus and heart disease, and infectious diseases such as norovirus, the flu, and athlete's foot. Procedure classifications list procedure code, which are used to capture interventional data. These diagnosis and procedure codes are used by health care providers, government health programs, private health insurance companies, workers' compensation carriers, software developers, and others for a variety of applications in medicine, public health and medical informatics, including:

<span class="mw-page-title-main">CE marking</span> Declaration of conformity with European standards

On commercial products, the letters CE mean that the manufacturer or importer affirms the goods' conformity with European health, safety, and environmental protection standards. It is not a quality indicator or a certification mark. The CE marking is required for goods sold in the European Economic Area (EEA), but is also found on products sold elsewhere that have been manufactured to EEA standards.

<span class="mw-page-title-main">Medical device</span> Device to be used for medical purposes

A medical device is any device intended to be used for medical purposes. Significant potential for hazards are inherent when using a device for medical purposes and thus medical devices must be proved safe and effective with reasonable assurance before regulating governments allow marketing of the device in their country. As a general rule, as the associated risk of the device increases the amount of testing required to establish safety and efficacy also increases. Further, as associated risk increases the potential benefit to the patient must also increase.

Title 21 CFR Part 11 is the part of Title 21 of the Code of Federal Regulations that establishes the United States Food and Drug Administration (FDA) regulations on electronic records and electronic signatures (ERES). Part 11, as it is commonly called, defines the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records.

Structured Product Labeling (SPL) is a Health Level Seven International (HL7) standard which defines the content of human prescription drug labeling in an XML format. The "drug labeling" includes all published material accompanying a drug, such as the Prescribing Information which contains a great deal of detailed information about the drug. As of Release 4 of the SPL standard, 22,000 FDA informational product inserts have been encoded according to the standard.

<span class="mw-page-title-main">Medical Devices Directive</span>

The Medical Device Directive is intended to harmonise the laws relating to medical devices within the European Union. The MD Directive is a 'New Approach' Directive and consequently in order for a manufacturer to legally place a medical device on the European market the requirements of the MD Directive have to be met. Manufacturers' products meeting 'harmonised standards' have a presumption of conformity to the Directive. Products conforming with the MD Directive must have a CE mark applied. The Directive was most recently reviewed and amended by the 2007/47/EC and a number of changes were made. Compliance with the revised directive became mandatory on 21 March 2010.

<span class="mw-page-title-main">Food and Drug Administration Amendments Act of 2007</span> US law

President of the United States George W. Bush signed the Food and Drug Administration Amendments Act of 2007 (FDAAA) on September 27, 2007. This law reviewed, expanded, and reaffirmed several existing pieces of legislation regulating the FDA. These changes allow the FDA to perform more comprehensive reviews of potential new drugs and devices. It was sponsored by Reps. Joe Barton and Frank Pallone and passed unanimously by the Senate.

A European Authorised Representative (E.A.R.) serves as a legal entity designated by non European Union (EU) manufacturers, to represent them in the EU and ensure their compliance with the European Directives. The CE certificate and declaration of conformity can only be issued by a company located in the European Union.

Unique Identification Marking, UID marking, Item Unique Identification or IUID, is a part of the compliance process mandated by the United States Department of Defense. It is a permanent marking method used to give equipment a unique ID. Marking is essential for all equipment with an acquisition cost of over $5,000, equipment which is mission essential, controlled inventory, or serially-controlled. UID-marking is a set of data for assets that is globally unique and unambiguous. The technology used to mark an item is 2D Data Matrix ECC 200 Symbol. UID marking can be used to ensure data integrity and data quality throughout an item's lifecycle; it also supports multi-faceted business applications.

<span class="mw-page-title-main">Notified body</span>

A notified body, in the European Union, is an organisation that has been designated by a member state to assess the conformity of certain products, before being placed on the EU market, with the applicable essential technical requirements. These essential requirements are publicised in European directives or regulations.

<span class="mw-page-title-main">Food and Drug Administration Modernization Act of 1997</span> US law

The United States Food and Drug Administration Modernization Act of 1997 (FDAMA) amended the Federal Food, Drug, and Cosmetic Act. This act is related to the regulation of food, drugs, devices, and biological products by the FDA. These changes were made in order to recognize the changes in the way the FDA would be operating in the 21st century. The main focus of this is the acknowledgment in the advancement of technological, trade, and public health complexities.

Global Medical Device Nomenclature (GMDN) is a system of internationally agreed generic descriptors used to identify all medical device products. This nomenclature is a naming system for products which include those used for the diagnosis, prevention, monitoring, treatment or alleviation of disease or injury in humans.

The Health Industry Business Communications Council (HIBCC) is a primary standard-setting and educational organization for healthcare bar coding in the United States. It provides publications, trade shows, educational resources, conferences and training programs.

Barcode technology in healthcare is the use of optical machine-readable representation of data in a hospital or healthcare setting.

<span class="mw-page-title-main">Food and Drug Administration Safety and Innovation Act</span> Piece of American regulatory legislation

The Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA) is a piece of American regulatory legislation signed into law on July 9, 2012. It gives the United States Food and Drug Administration (FDA) the authority to collect user fees from the medical industry to fund reviews of innovator drugs, medical devices, generic drugs and biosimilar biologics. It also creates the breakthrough therapy designation program and extends the priority review voucher program to make eligible rare pediatric diseases. The measure was passed by 96 senators voting for and one voting against.

Single-use medical device reprocessing is the disinfection, cleaning, remanufacturing, testing, packaging and labeling, and sterilization among other steps, of a used,, medical device to be put in service again. All reprocessed medical devices originally labeled for single use in the United States are subject to U.S. Food and Drug Administration (FDA) manufacturing requirements and must meet strict cleaning, functionality, and sterility specifications prior to use. Although first regulated in the U.S., the reprocessing of medical devices, particularly those that are labeled "Single Use Device" (SUDs), is a global practice with countries in Europe, Asia, Africa, and North America actively engaged in reprocessing. Currently, approximately 2% of all SUDs on the U.S. market are eligible for reprocessing by a qualified commercial vendor. Reprocessing industry estimates indicate the amount of revenue saved by hospitals that use reprocessed devices to be $471 million in 2018. Over 8,800 hospitals and surgical centers use reprocessed devices, in the U.S., Canada, Israel, Europe and Japan, according to the Association of Medical Device Reprocessors.

Reed Technology and Information Services Inc. is a company that provides electronic content management services, engaging in data capture and conversion, preservation, analysis, e-submission and publication for corporate, legal and government clients. The company was founded in 1961 and is based in Horsham, Pennsylvania, with an additional office in Alexandria, Virginia.

The distribution of medications has special drug safety and security considerations. Some drugs require cold chain management in their distribution.

<span class="mw-page-title-main">Regulation (EU) 2017/745</span> Political regulation

Regulation (EU) 2017/745 is a regulation of the European Union on the clinical investigation and sale of medical devices for human use. It repeals Directive 93/42/EEC (MDD), which concerns medical devices, and Directive 90/385/EEC, which concerns active implantable medical devices, on 26 May 2021.

References

  1. ↑ 衛生福利部食品藥物管理署 (2018-05-31). "醫療器材單一識別規範(104年10月)". 衛生福利部食品藥物管理署. Retrieved 2020-10-09.
  2. ↑ Ament, Lucy (November 13, 2006). "AHA calls for medical device identification system". AHA News. 42 (23): 2.
  3. ↑ DiConsiglio, John (September 2007). "Solve a unique challenge". Materials Management in Health Care. 16 (9): 24–26.
  4. ↑ DiConsiglio, John (September 2007). "Solve a unique challenge". Materials Management in Health Care. 16 (9): 26.
  5. ↑ Joch, Alan (October 2008). "A device by any other name". Materials Management in Health Care. 17 (10): 16.
  6. ↑ "Hospitals calling for device ID". Materials Management in Health Care. 17 (6): 4. June 2008.
  7. ↑ FDA - Compliance Dates for UDI Requirements. Accessed 16 July 2015
  8. ↑ "Unique Device Identification (UDI) System under the EU medical devices Regulations 2017/745 and 2017/746" (PDF). Health.ec.europa.eu. Retrieved July 23, 2022.
  9. ↑ What about Legacy devices
  10. ↑ "European database on medical devices" (PDF). health.ec.europa.eu. Retrieved 29 March 2022.
  11. ↑ COMMISSION IMPLEMENTING DECISION (EU) 2019/939 of 6 June 2019 designating issuing entities designated to operate a system for the assignment of Unique Device Identifiers (UDIs) in the field of medical devices
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.